

Zhe Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7367093/publications.pdf>

Version: 2024-02-01

34
papers

1,269
citations

394421

19
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

2219
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1/PD-L1 and immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2017, 407, 57-65.	7.2	235
2	LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 274.	8.6	83
3	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. <i>Oncotarget</i> , 2014, 5, 6983-6993.	1.8	76
4	NF- κ B in pancreatic cancer: Its key role in chemoresistance. <i>Cancer Letters</i> , 2018, 421, 127-134.	7.2	71
5	Role of the microbiome in occurrence, development and treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2019, 18, 173.	19.2	67
6	Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. <i>Molecular Cancer</i> , 2018, 17, 2.	19.2	61
7	miR-497 expression, function and clinical application in cancer. <i>Oncotarget</i> , 2016, 7, 55900-55911.	1.8	57
8	The dual functional role of MicroRNA-18a (miR-18a) in cancer development. <i>Clinical and Translational Medicine</i> , 2019, 8, 32.	4.0	55
9	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. <i>Cancer Letters</i> , 2017, 397, 94-102.	7.2	50
10	PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 133.	8.6	46
11	Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. <i>Oncotarget</i> , 2017, 8, 41575-41583.	1.8	46
12	MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations. <i>Frontiers in Oncology</i> , 2019, 9, 893.	2.8	41
13	OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. <i>Molecular Cancer Research</i> , 2020, 18, 685-697.	3.4	40
14	Glucagonoma and the glucagonoma syndrome (Review). <i>Oncology Letters</i> , 2018, 15, 2749-2755.	1.8	38
15	Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. <i>Clinical Cancer Research</i> , 2021, 27, 3383-3396.	7.0	36
16	The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094094.	3.2	35
17	Expression, function and clinical application of stanniocalcin-1 in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7686-7696.	3.6	31
18	CHIP: A new modulator of human malignant disorders. <i>Oncotarget</i> , 2016, 7, 29864-29874.	1.8	31

#	ARTICLE	IF	CITATIONS
19	The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. <i>Cells</i> , 2021, 10, 497.	4.1	28
20	Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. <i>Cancer Cell International</i> , 2020, 20, 66.	4.1	27
21	MiR-1178 Promotes the Proliferation, G1/S Transition, Migration and Invasion of Pancreatic Cancer Cells by Targeting CHIP. <i>PLoS ONE</i> , 2015, 10, e0116934.	2.5	19
22	Localized Autoimmune Pancreatitis. <i>Medicine (United States)</i> , 2015, 94, e1656.	1.0	18
23	Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. <i>Cancer Medicine</i> , 2019, 8, 6403-6413.	2.8	17
24	Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 8.	8.6	13
25	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. <i>Cancer Letters</i> , 2020, 485, 1-13.	7.2	10
26	Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic <i>E. coli</i> Infection Cause Pancreatic Cancer Progression Modulated by TUBB/Rho/ROCK Signaling Pathway? A Bioinformatic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-12.	1.9	10
27	A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy. <i>Journal of Gastroenterology</i> , 2021, 56, 938-948.	5.1	8
28	Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1637.	2.8	7
29	MicroRNA-381 is a Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 535665.	2.8	4
30	Surgical treatment of pancreatic head cancer: concept revolutions and arguments. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 392-6.	2.2	4
31	CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 345-355.	4.4	2
32	Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 862-877.	2.2	2
33	Risk factors of systematic biliary complications in patients with gallbladder stones. <i>Irish Journal of Medical Science</i> , 2020, 189, 943-947.	1.5	1
34	Analysis of clinical characteristics and treatment of pancreatic cystic tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 519-527.	2.2	0